MiniMed Group, Inc. 10-K

Item 7A. Quantitative and Qualitative Disclosures About Market Risk Currency Exchange Rate Risk Our operations are primarily located in the U.S., but we operate in over 80 countries globally. A significant portion of our sales are from EMEA, where fluctuations in the rate of exchange between the U.S. dollar and the local currencies could adversely affect our financial results, including income and losses as well as assets and liabilities. During the fiscal year ended April 24, 2026, the Company’s net sales in international markets was approximately 70% of the total Company net sales, as compared to 67% for the fiscal year ended April 25, 2025. Due to the global nature of our operations, we are exposed to currency exchange rate changes, which may cause fluctuations in earnings and cash flows. For example, a 10% strengthening or weakening of the major non-U.S. currencies against the U.S. dollar in the fiscal year ended April 24, 2026 would have resulted in an increase/decrease to net sales by approximately $218 million, as compared to $180 million for the fiscal year ended April 25, 2025. Interest Rate Risk We are subject to interest rate risk on our borrowings. We manage interest rate risk in the aggregate, while focusing on our immediate and intermediate liquidity needs. We had no borrowings outstanding as of April 24, 2026. We are exposed to interest rate changes affecting the yield on our investments in money market funds; such exposure is not considered material. For a discussion of current market conditions and the impact on our financial condition and results of operations, please see the “Liquidity” section of the Management's Discussion and Analysis. For additional discussion of market risk, refer to Note 6, “Financial Instruments”, to the consolidated financial statements. 107